ZCZahra Chaichy

Zahra Chaichy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zahra Chaichy has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bioinformatics analysis of differentially expressed genes in pediatric multiple sclerosis; identification of key biomarkers and therapeutic targets

    by Zahra Chaichy, Maryam Naseri, Yasaman Fatemeh Khazaee, Gholamreza Khademi, Majid Sezavar

    Introduction: Pediatric-onset multiple sclerosis (POMS) is a rare but severe form of MS that presents before the age of 18, leading to long-term disability. Despite its clinical significance, the molecular mechanisms driving POMS remain poorly understood. Objectives: This study aims to identify key genes, pathways, and potential therapeutic targets involved in POMS using integrative bioinformatics approaches. Materials and Methods: In this in silico study, gene expression profiles from peripheral blood mononuclear cells of POMS patients and healthy controls were analyzed using the GEO2R platform (GSE203241 dataset). Differentially expressed genes (DEGs) were identified using adjusted P value < 0.05 and a fold change>1.1 or <-1.1. Gene ontology (GO) and pathway enrichment analyses were conducted using BiNGO and Enrichr to explore biological functions and dysregulated pathways. A protein-protein interaction (PPI) network was constructed using STRING (search tool for the retrieval of interacting genes/proteins) and analyzed by Cytoscape with CytoHubba and CytoCluster plugins to identify hub genes and functional modules. Promoter motif analysis was conducted using Tomtom and GoMo to uncover regulatory elements, while DrugBank was utilized to identify potential drug-target interactions. Results: A total of 1101 DEGs were identified, with enrichment in immune response pathways, cytokine signaling, and interferon responses. PPI network analysis revealed 15 hub genes, with MYC, HSP90AA1, JUN, HSPA4, and HIF1A identified by two independent algorithms, highlighting their central role in POMS. CytoCluster analysis uncovered functional modules related to RNA metabolism and vesicle transport. Promoter motif analysis revealed transcription factor binding sites that could influence hub gene expression. Drug-target analysis identified Food and Drug Administration (FDA)-approved and investigational drugs that interact with key hub proteins, offering potential therapeutic candidates. Conclusion: This study provides a comprehensive molecular overview of POMS, identifying critical genes, regulatory elements, and potential drug targets. These findings offer valuable insights into POMS pathogenesis and highlight novel avenues for therapeutic intervention, advancing the prospects for personalized treatment strategies in pediatric MS.


  • Open Access

    The challenges in diagnosis of multisystem inflammatory syndrome in children (MISC), comparison of MISC and drug eruption: A case report

    by Zahra Chaichy, Nasrin Moazzen, Mohammadhasan Aelami, Mahdieh Vahedi, Amir Amirabadi, Omid Khosravi, Amirali Aali, Hamid Ahanchian

    Unusual manifestations are possible for multi-system inflammatory syndrome brought on by SARS-Cov2 infection. Early diagnosis and effective treatment have a direct impact on the outcome. Every young patient who presents to the clinic with a fever, skin rash, stomach discomfort, or cardiovascular complications has to be evaluated for this potentially fatal disease. It is also of utmost importance to differentiate MIS-C from drug hypersensitivity (DHS). MIS-c highly resembles DHS but leads to more complications and a higher mortality rate. We report a 9-year-old female who initially presented with generalized abdominal pain, nausea, vomiting, and cough. She gradually developed an acute abdomen and was admitted for surgical management of a suspected perforated appendix. Her condition deteriorated despite surgery and medical treatment. Differentiating drug allergy from this new emerging syndrome can be difficult. Herein we discuss about it.